Last reviewed · How we verify
NCT07209943
Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro
NA trial testing Cognixion + Apple Vision Pro in ALS (Amyotrophic Lateral Sclerosis) in 10 participants. Not yet recruiting.
30 April 2026
Quick facts
| Lead sponsor | Cognixion |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 10 |
| Start date | 16 October 2025 |
| Primary completion | 30 April 2026 |
| Estimated completion | 31 May 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cognixion + Apple Vision Pro
Conditions studied
- ALS (Amyotrophic Lateral Sclerosis) — all drugs for ALS (Amyotrophic Lateral Sclerosis) →
- TBI Traumatic Brain Injury — all drugs for TBI Traumatic Brain Injury →
- SCI - Spinal Cord Injury — all drugs for SCI - Spinal Cord Injury →
- Stroke — all drugs for Stroke →
Sponsor
Cognixion
Who can join
18 and older, any sex, with ALS (Amyotrophic Lateral Sclerosis) or TBI Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is refine the usability of a BCI capable communication platform. The study will take place in the United States area and will enroll up to 10 participants with late stage ALS, traumatic brain injury (TBI) or spinal cord injury (SCI) that have assistive communication and computer control needs. Each subject will receive an integrated Cognixion + Apple Vision Pro device that includes an augmented reality brain computer interface and associated communication software. The study duration is 3-4 months for each participant. The key questions that will be addressed in this study are: 1. Identify the ability of individuals with target indications to use the integrated Cognixion-Apple Vision Pro system to communicate effectively. 2. Identify the ability of such individuals to learn to use BCI, ET-BCI and other modalities, and to measure their progress over time. 3. Identify the effectiveness of the different forms of input supported by the combined Cognixion-Apple Vision Pro system (BCI, eye-tracking) in allowing such individuals to communicate and have agency. 4. Identify how input such as BCI can be optimized to suit the needs of individuals (e.g., specific frequencies that work best for an individual, SNR with different frequencies, number of targets, length of recording for each frequency) and improve overall usability. 5. Identify the extent to which personalization through a large language model (LLM) affects communication. 6. Identify the appropriate capabilities to enable through an agentic communication interface. Key measures include: ITR - information transfer rate SUS - system usability scale
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07209943
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ALS (Amyotrophic Lateral Sclerosis)
Currently open trials in the same condition.
- NCT07067229 — Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron Disease · NA · recruiting
- NCT07006571 — At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis · NA · recruiting
- NCT07175935 — Amyotrophic Lateral Sclerosis Registry in Thailand · recruiting
- NCT07235111 — Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases · recruiting
- NCT06810219 — Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS · NA · recruiting
Other Cognixion trials
Trials by the same sponsor.
- NCT06810219 — Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07209943 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cognixion
- Last refreshed: 7 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07209943.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing